FASEB J. Integrated DNA Technologies
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.09-134882.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Buy
Right arrow All Versions of this Article:
fj.09-134882v1
23/11/3865    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Elmasri, H.
Right arrow Articles by Cataltepe, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elmasri, H.
Right arrow Articles by Cataltepe, S.
(The FASEB Journal. 2009;23:3865-3873.)
© 2009 FASEB

Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells

Harun Elmasri*, Cagatay Karaaslan*, Yaroslav Teper*, Elisa Ghelfi*, MeiQian Weng*, Tan A. Ince{dagger}, Harry Kozakewich{ddagger}, Joyce Bischoff§ and Sule Cataltepe*,1

* Division of Newborn Medicine and

{dagger} Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; and

{ddagger} Department of Pathology and

§ Department of Vascular Biology, Children’s Hospital, Boston, Massachusetts, USA

1 Correspondence: Division of Newborn Medicine, Brigham and Women’s Hospital, Thorn 1019, 75 Francis St., Boston, MA 02115, USA. E-mail: scataltepe{at}partners.org

Fatty acid binding protein 4 (FABP4) plays an important role in maintaining glucose and lipid homeostasis. FABP4 has been primarily regarded as an adipocyte- and macrophage-specific protein, but recent studies suggest that it may be more widely expressed. We found strong FABP4 expression in the endothelial cells (ECs) of capillaries and small veins in several mouse and human tissues, including the heart and kidney. FABP4 was also detected in the ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy and ECs. In most of these cases, FABP4 was detected in both the nucleus and cytoplasm. FABP4 mRNA and protein levels were significantly induced in cultured ECs by VEGF-A and bFGF treatment. The effect of VEGF-A on FABP4 expression was inhibited by chemical inhibition or short-hairpin (sh) RNA-mediated knockdown of VEGF-receptor-2 (R2), whereas the VEGFR1 agonists, placental growth factors 1 and 2, had no effect on FABP4 expression. Knockdown of FABP4 in ECs significantly reduced proliferation both under baseline conditions and in response to VEGF and bFGF. Thus, FABP4 emerged as a novel target of the VEGF/VEGFR2 pathway and a positive regulator of cell proliferation in ECs.—Elmasri, H., Karaaslan, C., Teper, Y., Ghelfi, E., Weng, M., Ince, T. A., Kozakewich, H., Bischoff, J., Cataltepe, S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.


Key Words: angiogenesis • infantile hemangioma • microvessel • placenta







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The Federation of American Societies for Experimental Biology.